Regulating fate decisions of anti-cancer T cells

[1]  T. Marafioti,et al.  A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. , 2014, Blood.

[2]  M. Smithey,et al.  Immune Memory–Boosting Dose of Rapamycin Impairs Macrophage Vesicle Acidification and Curtails Glycolysis in Effector CD8 Cells, Impairing Defense against Acute Infections , 2014, The Journal of Immunology.

[3]  R. Figlin,et al.  Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. , 2014, Cancer research.

[4]  E. Gilboa,et al.  Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. , 2014, The Journal of clinical investigation.

[5]  P. Muranski,et al.  Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. , 2013, The Journal of clinical investigation.

[6]  E. Yang,et al.  Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen , 2013, Nature Immunology.

[7]  C. Hess,et al.  Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch , 2013, Nature Immunology.

[8]  Thomas Höfer,et al.  Disparate Individual Fates Compose Robust CD8+ T Cell Immunity , 2013, Science.

[9]  T. Schumacher,et al.  Heterogeneous Differentiation Patterns of Individual CD8+ T Cells , 2013, Science.

[10]  R. Ahmed,et al.  mTOR, linking metabolism and immunity. , 2012, Seminars in immunology.

[11]  C. Meyer,et al.  The three main stumbling blocks for anticancer T cells. , 2012, Trends in immunology.

[12]  Qingsheng Li,et al.  Regulating Mammalian Target of Rapamycin To Tune Vaccination-Induced CD8+ T Cell Responses for Tumor Immunity , 2012, The Journal of Immunology.

[13]  M. Horton,et al.  Regulation of immune responses by mTOR. , 2012, Annual review of immunology.

[14]  R. V. Dúran,et al.  Regulation of TOR by small GTPases , 2012, EMBO reports.

[15]  I. Melero,et al.  Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer , 2011, Clinical Cancer Research.

[16]  Martin Pule,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[17]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[18]  J. Waxman,et al.  CD3 limits the efficacy of TCR gene therapy in vivo. , 2011, Blood.

[19]  A. Schambach,et al.  Retroviral and transposon-based tet-regulated all-in-one vectors with reduced background expression and improved dynamic range. , 2011, Human gene therapy.

[20]  W. Burns,et al.  Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. , 2011, Blood.

[21]  Qingsheng Li,et al.  The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. , 2010, Immunity.

[22]  Yun Ji,et al.  Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity , 2009, Proceedings of the National Academy of Sciences.

[23]  R. Ahmed,et al.  mTOR regulates memory CD8 T cell differentiation , 2009, Nature.

[24]  P. Muranski,et al.  Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells , 2009, Nature Medicine.

[25]  P. Allen,et al.  Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. , 2009, Cancer research.

[26]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  David K. Finlay,et al.  Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking , 2008, Nature Immunology.

[28]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[30]  J. Brayer,et al.  Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.

[31]  J. Blenis,et al.  Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. , 2002, Genes & development.

[32]  Hao Jiang,et al.  Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. , 2012, Cellular signalling.